Case File Banner 24

Roundtable: Balancing Safety Concerns With Unmet Needs in Wet AMD and DME Therapy

Show Description +

In an era concerned with safety, how do retina specialists balance their desire to access more durable therapies with the realities of safety? Priya Sharma Vakharia, MD; Joseph M. Coney, MD, and Jordan M. Graff, MD, provide insights on how high-dose aflibercept (Eylea, Regeneron) fits into the treatment landscape, what levels of drug-related risk they tolerate in patients with wet AMD and DME, and how the latest real-world positive safety data for faricimab (Vabysmo, Genentech/Roche) inform their treatment decisions.

Posted: 10/03/2023

Up Next


Roundtable: Navigating the Treatment Landscape, and a Look at the Pipeline

Ferhina Ali, MD; Ash Abbey, MD; and Scott Walter, MD, MSc,

Roundtable: When and How to Approach Using Newly Approved Anti-VEGF Agents

Priya Sharma Vakharia, MD; Joseph M. Coney, MD; and Yasha S. Modi, MD

Real-World Treatment-Naïve Case: Bilateral Wet AMD in a 92-Year-Old Patient

Priya Sharma Vakharia, MD, Joseph M. Coney, MD, and Jordan M. Graff, MD

Real-World Switch Case: Wet AMD Therapy in a Patient Averse to Injections

Priya Sharma Vakharia, MD, Joseph M. Coney, MD, and Jordan M. Graff, MD

Real-World Treatment-Naïve Case: Treating DME With a Dual-Inhibition Approach

Priya Sharma Vakharia, MD, Joseph M. Coney, MD, and Jordan M. Graff, MD

Real-World Step Therapy Case: A Challenging DME Patient

Priya Sharma Vakharia, MD, Joseph M. Coney, MD, and Jordan M. Graff, MD

Real-world Switch Case: Wet AMD Patient Who Relies on Family for Transportation

Priya Sharma Vakharia, MD, Joseph M. Coney, MD, and Jordan M. Graff, MD

Roundtable: Balancing Safety Concerns With Unmet Needs in Wet AMD and DME Therapy

Priya Sharma Vakharia, MD, Joseph M. Coney, MD, and Jordan M. Graff, MD

Roundtable: Balancing Safety Concerns With Unmet Needs in Wet AMD and DME Therapy

In an era concerned with safety, how do retina specialists balance their desire to access more durable therapies with the realities of safety? Priya Sharma Vakharia, MD; Joseph M. Coney, MD, and Jordan M. Graff, MD, provide insights on how high-dose aflibercept (Eylea, Regeneron) fits into the treatment landscape, what levels of drug-related risk they tolerate in patients with wet AMD and DME, and how the latest real-world positive safety data for faricimab (Vabysmo, Genentech/Roche) inform their treatment decisions.

Posted: 10/03/2023


Please log in to leave a comment.